Your cannabis customer can pay you on time for a year and still be one bad month away from taking you down with them.
That is what a true predictive commercial credit report shows you, and what an association’s pooled, self-reported data can miss.
The difference, and what causes that takedown, is Capital, the third of the 5 Cs of Credit.
As I wrote about previously, Character asks whether a customer will pay. Capacity asks whether they can generate the cash. Capital asks a different question: what’s behind your customer, financially, when something goes wrong?
What capital really measures.
In B2B trade, capital is the cushion a customer needs to absorb a shock, a big customer defaulting, a sudden drop in prices, without missing payments to their own suppliers.
That includes you.
Think of it as bench depth. A team looks strong until a couple of players go down, then you learn how deep the roster is.
When that cushion is thin, one delinquent customer can lock up their working capital fast, and it rolls downstream to you. Thin capital doesn’t stay their problem. It becomes yours.
Where a customer’s capital comes from matters, a lot.
How a company is funded tells you how deep the cushion is:
1. VC-backed — Long runway, high burn. The question is whether the next round comes in, or the investor walks.
2. PE-backed — Professionally run but often carrying debt. Watch whether the sponsor adds cash when things get tight or protects its own position first.
3. Founder or family funded — Committed and stable, but usually thinner on capital depth. If a major customer doesn’t pay, there’s no institutional backstop keeping suppliers paid. No one warms up in the bullpen.
Why this hits cannabis harder.
Most industries have deep access to bank lines and institutional capital. Cannabis has had far less of both. Federal restrictions keep many lenders and investors cautious, and the banking and tax environment is tougher on cash than almost anywhere.
Thin capital in cannabis is often structural. It’s not a knock on the operator. It’s the environment they’ve been forced to build in.
How the gap could get filled.
Specialty finance players have stepped in where banks won’t. Factoring has evolved into fintech tools: buy-now-pay-later, AR financing, invoice-to-cash advances. They pay the seller upfront and extend terms to the buyer. That helps liquidity, but only for a small number of companies.
Financing and credit intelligence aren’t the same layer, though. These tools move the cash. They don’t tell a supplier who’s good for the terms, how much exposure to carry, or whose payment behavior is slipping. Everyone extending credit in cannabis, suppliers and financers alike, works with less shared payment data than other industries have relied on for decades.
That’s the gap. Capital moves the money. Credit intelligence tells you whom to move it to, and how much. That is what Reklaim Credit Solutions is being built to bring to the cannabis industry.